Ramucirumab, an anti-VEGFR2 antibody14, and apatinib, a VEGFR2 tyrosine kinase inhibitor15, have been shown to prolong OS and were approved for second-line and third-line treatment of advanced gastric cancer, respectively. This evidence concerns the gene KDR and gastric cancer.